,27 Silencing ChREBP reduces triglyceride content in the liver, specifically through the inhibition of glucose-induced lipogenesis, whereas hepatic ChREBP overexpression leads to steatosis and increased DNL. The gene discussed is MLXIPL; the disease is steatosis.